Mirabegron
- Generic Name
- Mirabegron
- Brand Names
- Myrbetriq, Betmiga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24N4O2S
- CAS Number
- 223673-61-8
- Unique Ingredient Identifier
- MVR3JL3B2V
- Background
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
- Indication
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00776516
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- Conditions
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2792
- Registration Number
- NCT00688688
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- Conditions
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2336
- Registration Number
- NCT00689104
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2149
- Registration Number
- NCT00662909
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
- Conditions
- Interventions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 200
- Registration Number
- NCT00410514
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.